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Abstract: Vitamin E, a naturally occurring antioxidant, has been found to reduce atherosclerotic 
lesion formation in animal models as well as cardiovascular morbidity in several observational 
studies. However, a number of case-control and prospective cohort studies failed to confirm its 
value in the primary and secondary prevention of morbidity and mortality from coronary artery 
disease. Several small or larger randomized interventional trials completed to date failed to resolve 
the conflict. Notably, even in large, well-conducted prospective epidemiologic studies, the potential 
effects of residual confounding may be on the same order of magnitude as the reported benefit. The 
response to vitamin E supplementation in specific patient subpopulations with chronic inflamma-
tion and/or higher degrees of oxidative stress has not been studied as yet. Therefore, further large 
randomized interventional trials are warranted to clarify accurately the role of vitamin E in the 
primary and secondary prevention of atherosclerotic coronary disease in these patient groups.
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Introduction
Oxidative modification of low-density lipoprotein is an important step in the 
development and progression of atherosclerosis in experimental studies,1 and anti-
oxidants such as vitamin E have been shown to slow atherosclerosis.2,3 An inverse 
relation has been observed between coronary heart disease and the consumption of 
fruits, vegetables, and other foods containing vitamins, particularly vitamin E as well 
as the concentrations of α-tocopherol (α-Τ).4–7 Observational studies have indicated 
that persons who consume more than 100 IU of α-Τ per day for more than two years 
have lower rates of coronary events and lower rates of progression of coronary artery 
lesions.4,8–11 However, observational studies cannot prove a genuine etiologic relation 
between the lower risk of coronary heart disease and α-Τ consumption. Despite this, 
randomized, controlled trials of antioxidant vitamins in cardiovascular disease have 
thus far yielded largely conflicting results12–17 for reasons discussed further below. 
We provide herein an update of the literature on this issue and discuss the existing data 
from α-T supplementation studies in the general population as well as the data from the 
use of vitamin-E coated dialyzers in end-stage renal disease (ESRD) patients, which 
we believe add further information on the antiatherogenic effects of α-Τ.
Mechanisms of action
Vitamin Ε is consisted of a group of eight fat-soluble complexes, namely α-, β-, γ-, 
and δ-tocopherols as well as α-, β-, γ-, and δ-tocotrienoles. Commercially available 
forms contain vitamin E as the natural RRR-α-tocopherol (RRR-α-Τ), as the synthetic Vascular Health and Risk Management 2009:5 768
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α-tocopherol (rac-α-T), or as a mixture of both. Different 
vitamin E complexes have different bioavailability, the α-T 
being preferentially transferred by α-tocopherol transfer 
protein (α-TTP) into plasma lipoproteins (high-density lipo-
protein [HDL] and low-density lipoprotein [LDL]), forming 
a complex which protects them from peroxidation by free 
radicals. This difference in bioavailability between different 
vitamin E complexes confers special functional capacities in 
α-T compared to other tocopherols and tocotrienols. In the 
molecular level, the central role of vitamin E in the protection 
against lipid peroxidation is exerted through its function as 
hydrogen donor to lipid peroxide radicals. One major category 
of actions of oral supplementation with α-T is related to the 
increase in the resistance of LDL to oxidation and the decrease 
in the cytotoxicity of oxidized LDL toward endothelial cells, 
which is known to play a pivotal role in the atherogenetic 
process.18,19 In brief, enhanced protection of LDL against 
oxidation is associated with a number of vascular effects that 
would be expected to reduce the clinical activity of coronary 
artery disease: reduced plaque rupture, platelet adhesion, and 
vasospasm. Beyond the protection against LDL oxidation, α-Τ 
converts in parallel multiple other actions (Table 1), such as the 
inhibition of smooth muscle cell proliferation, the maintenance 
of normal endothelial cell function, the decrease in the levels 
of soluble adhesion molecules and inhibition of monocyte-
endothelial cell adhesion, inhibition of monocyte release of 
reactive oxygen species (ROS) and inflammatory cytokines 
(interleukin-1β [IL-1β], interleukin-6 [IL-6], tumor necrosis 
factor-α [TNF-α]), the decrease in the levels of soluble 
platelet activation inhibitor-1 (PAI-1), and inhibition of platelet 
adhesion and aggregation. Moreover, α-Τ regulates signal 
transduction and gene expression in different cell pathways, 
through special interactions with enzymes such as protein 
kinase C and Β, protein phosphatase 2A, diacylglycerol kinase, 
phospholipase A2, cycloxygenase 2, and 5-lipoxygenase 
(5-LOX), structural proteins, lipids, and transcription factors.20 
Furthermore, tocopherols affect certain enzymes, such as 
3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase and 
cytochrome P450 enzymes, transcription factors and receptors, 
such as LDL receptors, scavenger receptors CD36 and BI, at a 
transcriptional level. Finally, antioxidative effects of α-Τ them-
selves lead to a decrease in inflammation, through the increase 
in bioavailability of endothelial nitric oxide (NO), which 
suppresses of the expression of the genes of several inflam-
matory molecules, such as monocyte chemotactic protein-1 
(MCP-1), P-selectin, and vascular cell adhesion molecule-1 
(VCAM-1).21 Though several studies have supported slow 
progression and prevention of atherosclerosis with α-Τ,22,23 
the exact vasoprotective role of vitamin E is still evasive even 
though recent reports have questioned the role of vitamin E 
in the atherogenetic process.24,25
Controversies of the clinical trials
Epidemiological studies over the last years suggest that low 
levels of antioxidants are associated with increased risk for 
cardiovascular disease and that increased intakes appear 
to be protective. Moreover, several studies have revealed a 
relationship between antioxidant vitamins and early carotid 
artery atherosclerosis, determined by B-mode ultrasound 
measurement of carotid artery intima-media thickness 
(IMT).26,27 Despite the aforementioned evidence, there has 
been an unexpected discrepancy between the anticipated 
cardiovascular benefits and the results of major prospective 
primary and secondary prevention clinical trials. For example, 
in the Alpha-Tocopherol, Beta Carotene (ATBC) study,15 the 
incidence of myocardial infarction, cardiovascular events 
and cardiovascular mortality did not differ in participants 
randomly assigned to α-Τ (50 IU/day) compared with those 
assigned to placebo. In the Heart Outcomes Prevention 
Evaluation (HOPE) Study,16 a double-blind, randomized trial 
conducted to evaluate the effects of ramipril and vitamin E 
(400 IU/day) in 9541 patients at high risk for cardiovascular 
events, it was found that treatment with vitamin E for a mean of 
4.5 years had no apparent effect on cardiovascular outcomes. 
In the open-label, nonplacebo-controlled Primary Prevention 
Project17 in the general population, α-Τ supplementation 
(300 IU/day) for four years had no significant impact on the 
incidence of myocardial infarction, cardiovascular events, 
cardiovascular mortality or all-cause mortality, compared to 
controls. Of the major randomized controlled trials of α-Τ 
supplementation for secondary prevention of cardiovascular 
events, Cambridge Heart Antioxidant Study (CHAOS)14 
Table 1 Nonantioxidant and regulatory functions of vitamin e
inhibition of smooth muscle cell proliferation
Maintenance of normal endothelial cell function
Decrease in the levels of soluble adhesion molecules
inhibition of monocyte-endothelial cell adhesion
Inhibition of monocyte release of ROS and inflammatory cytokines
Decrease in the levels of soluble PAi-1
inhibition of platelet adhesion and aggregation
Signal transduction regulation and gene expression in different 
cell pathways
Regulation of enzymes, transcription factors and receptorsVascular Health and Risk Management 2009:5 769
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was the only one to describe a significantly reduced risk for 
myocardial infarction and all cardiac events after 1.5 years 
of α-Τ supplementation. However, it was encumbered by 
design problems, including unbalanced randomization, 
incomplete follow-up, and a mid-study change in α-Τ dose 
(800 IU/d to 400 IU/d).28 In the largest of the secondary 
prevention trials, open-label, nonplacebo-controlled GISSI-P 
(Gruppo Italiano per lo Studio della Sopravvivenza n’nfarto 
miocardico-Prevenzione) study, combined primary and 
cardiovascular end points were not significantly reduced in the 
two-way or four-way analyses comparing α-Τ supplements 
with no treatment.29 In secondary analyses, α-Τ supplemen-
tation significantly reduced cardiovascular death, including 
cardiac, coronary, and sudden deaths, in the four-way but 
not the two-way analysis. The Secondary Prevention with 
Antioxidants of Cardiovascular disease in End-stage renal 
disease (ESRD) (SPACE) study30 was a double-blind, 
placebo-controlled, randomized, secondary prevention trial in 
hemodialysis patients. The primary endpoint was a composite 
variable consisting of myocardial infarction, ischemic stroke, 
peripheral vascular disease, and unstable angina. In addition 
to a significant increase in α-Τ levels, RRR-α-Τ (800 IU/d) 
significantly decreased the primary endpoint by 54%. Finally, 
several meta-analyzes failed to confirm any significant benefit 
in primary or secondary cardiovascular prevention.31,32
Confounding factors
Even though the majority of the randomized trials have 
shown a significant reduction in cardiovascular endpoints, 
they failed in general to show parallel improvement in 
cardiovascular mortality, probably due to their insufficient 
statistical power to examine mortality as an endpoint. In the 
bottom line, there appears to be a potential 30%–60% reduc-
tion in cardiovascular endpoints with antioxidant therapy in 
the form of oral α-Τ, the patient’s level of risk as well as the 
dosing and duration of therapy being important factors. The 
discrepancy between the findings in the observational and 
intervention studies could be well attributed to the presence 
of uncontrolled factors associated with increased α-Τ intake 
that might underlie the observed protective effects, in as 
much as the effect of uncontrolled confounders may well be 
of the same magnitude as the anticipated risk reduction with 
α-Τ use. Therefore, more conclusive data obtained through 
randomized controlled trials should be taken into account 
before making definitive recommendations.
Surprisingly, in most of the intervention studies, no 
measurement was made of oxidative stress and, thus, it was 
impossible to conclude whether the interventions actually 
modified oxidative stress in the patients. Furthermore, the rate 
constant for the reaction of α-Τ with O2 radicals is up to five 
orders of magnitude slower (k = 2.5 × 106 M-1s-1) than the rate 
of reaction of O2 radicals with endogenous antioxidant enzymes 
and molecules such as superoxide dismutase (SOD) and NO.33 
Because oral intake of α-Τ only modestly increases its plasma 
and tissue levels, this slow rate of reaction with ROS means that 
α-Τ, at the concentrations reached in tissue, is unlikely to affect 
biological outcomes. Rational evaluation of combination and 
novel antioxidant therapies seems desirable. Furthermore it is 
important to remember that much higher doses of these vita-
mins have been used in model systems than are administered in 
clinical trials. Moreover, differences in activity between synthetic 
and natural tocopherols used in different studies might account 
for the large discrepancies between their findings. Finally, 
as long as α-Τ is associated with the lipophilic/hydrophobic 
domains of lipoproteins and cell membranes, while ROS are 
generated in the cytosolic and extracellular compartments, the 
reaction between them is not always self-evident. Therefore, α-Τ 
form bioavailability in different intervention studies seems also 
to be a matter of concern, especially for cell signaling, as long 
as most of the reported anti-inflammatory effects of α-Τ seem 
to be due to RRR-α-Τ.
Optimal dosing, duration, and timing 
of therapy
With respect to vitamin E requirements for reducing total and 
cause-specific mortality, it is important to note that significant 
reductions in risk were observed as serum α-Τ values increased 
from 9.1 mg/L (21 µmol/L) to ∼13 mg/L (30 µmol/L).34 
In general, serum α-Τ concentrations are poorly correlated 
with dietary vitamin E estimates and optimal dosing and 
duration of therapy have yet to be established. Further basic 
investigation will be necessary to clarify the potential multiple 
mechanisms through which antioxidant therapy impacts on the 
progression and clinical manifestations of coronary athero-
sclerosis because this will help us to formulate more rational 
“antioxidant” treatment strategies as well as better designed 
clinical trials. Optimal dosing, duration, and timing of therapy 
ought rest on a more thorough understanding of whether the 
primary effect is on lesion formation/progression versus some 
alteration of the intrinsic character of the plaque that renders 
it resistant to rupture, or alternatively, that the main impact 
of α-Τ is extrinsic to the lesion via effects on platelet adhe-
sion/aggregation, the coagulation cascade, cell proliferation, 
or NO-dependent vasodilatation. For example, in the ATBC 
trial,35 daily treatment with 50 mg of α-Τ for five to eight years 
had no effect on the risk of death from coronary heart disease, Vascular Health and Risk Management 2009:5 770
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despite the significant increase in the median level of α-Τ, from 
28.5 µmol/L at baseline to 42.5 µmol/L at three months. In 
the CHAOS Study, a large reduction in the number of patients 
with nonfatal myocardial infarction after a median follow-up 
of 1.4 years of treatment with α-Τ was found, concomitantly 
with a significant increase in the mean α-Τ levels, from 34.2 to 
51.1 µmol/L in patients receiving 400 IU of vitamin E per day 
and to 64.5 µmol/L in patients receiving 800 IU per day.14 Within 
the Health Professionals Follow-up Study (HPFS), a trend 
toward benefit was found with daily consumption of only 25 IU 
but this protective effect did not achieve statistical significance 
until doses were as high as 100 IU/d. Maximal benefit was seen 
at a dosing range of 100–249 IU/d, with no further decrease 
in risk detected in subjects taking 250 IU/day.36 Similarly, the 
Nurses’ Health Study (NHS) demonstrated a potential protec-
tive effect at doses under 100 IU/day but with wide confidence 
intervals. In the majority of recently completed and ongoing 
interventional trials doses of at least 400 IU/d was considered 
appropriate.37 It seems that there might be a threshold dose of 
α-Τ that might be effective, ie, 800 IU/d. However, a definitive 
beneficial dose scheme of α-T weighted over its possible toxicity 
has not been found until now. On the other hand, precautions 
regarding the safety of vitamin E, especially at higher doses, are 
important to bear in mind, as long as there several studies raised 
concerns about potential harmful effects caused by vitamin E 
supplementation, especially hemorrhagic stroke.35
With respect to duration of treatment, again it is difficult 
to establish a consensus. Both the HPFS and NHS did not 
observe a statistically significant benefit until after two years 
of α-Τ supplementation. Among interventional trials, several 
smaller studies have demonstrated no risk reduction with 
shorter duration of therapy at much higher doses. CHAOS 
recently confirmed a delay of benefit until after 200 days of 
therapy. As noted previously, the ATBC trial, which employed a 
lower dose of α-Τ, observed only a marginal effect, even with 
4.7 years of treatment. There were not sufficient numbers of 
subjects in either HPFS or NHS taking α-Τ supplements for an 
adequate duration to detect a significant time-dependent ben-
efit of therapy beyond two years. However, a suggestive trend 
was evident in the HPFS. Finally, it is important to consider 
the effects of dietary α-Τ alone. Within both the NHS and the 
HPFS, dietary α-Τ (observed median, 7.7 IU/d; range, 6.3–100 
IU/d) did not appear to have any protective effect, and thus it 
has been widely held that high-dose supplementation is neces-
sary to achieve substantial benefit. Combining the data from all 
trials of α-Τ indicates that such treatment has little effect on the 
risk of death or cardiovascular events, at least over a four-to-
six-year period. Since the primary mechanism of these agents 
may be the prevention of new lesions, α-T may have to be used 
for more than five years to have a demonstrable benefit.
It is possible that oxidant stress, while elevated, is a 
marginal player in the end points (usually myocardial 
infarction, persistent angina, stroke, and vascular death) 
measured in clinical trials and that ROS generation is more 
relevant to initiation of the process, rather than its culmination. 
Late lethal cardiovascular events, on the other hand, involve 
not only the development of the atherosclerotic plaque, but 
also plaque rupture, vasoconstriction, and local thrombosis, 
resulting in partial or total arterial obstruction. In contrast to the 
majority of studies linking antioxidants with decreased athero-
sclerosis in animals, most trials in humans were initiated when 
atherosclerosis was already established. Although in humans 
supplementation with lipid-soluble antioxidants protects 
LDL against ex vivo oxidation, prevention of the initiating 
events in atherosclerosis may not be the principal mechanism 
responsible for the reduction in the clinical manifestations 
of atherosclerosis that has been linked to higher antioxidant 
intake. In the subjects in the NHS and the HPFS, it is likely 
that atherosclerosis was already present, because autopsy data 
from other studies indicate that atherosclerotic lesions are 
already established in childhood.38 In the Cambridge Heart 
Antioxidant Study, all the subjects had radiographic evidence 
of atherosclerosis. Thus, any explanation of the epidemiologic 
results must address the issue of pre-existing atherosclerotic 
lesions. Antioxidants could limit the clinical expression of 
coronary artery disease by causing the regression or slowing 
the progression of coronary atherosclerotic lesions.
The role of inflammation
Chronic inflammation is known to play a pivotal role in the 
atherogenetic process, in interplay with oxidative stress. 
Recently, studies in patients with chronic inflammation provided 
evidence linking markers of inflammation and oxidative 
stress.39–42 Recently, solid evidence revealed that inflammation 
aggravates oxidative stress and vice versa, interactions 
which take place through activation of the transcription 
factor NF-κB, a regulator of several genes implicated 
in atherogenesis, such as genes coding for intracellular 
adhesion molecule-1 (ICAM-1) and vascular cellular 
adhesion molecule-1 (VCAM-1) and cytokines. α-T acetate 
and succinate have been shown to inhibit TNF-α–induced 
NF-κB activation in vitro. Thus, α-Τ has been shown to have 
beneficial effects in inhibiting monocyte-endothelial adhesion 
when incubated with either endothelial cells or monocytes, and 
it is very likely that following supplementation it partitions 
into both monocytes and endothelial cells, and its ability to Vascular Health and Risk Management 2009:5 771
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reduce monocyte-endothelial cell adhesion is greater. Several 
groups have shown that α-Τ supplementation in humans has 
various anti-inflammatory effects both in vivo and in vitro, 
such as the decrease in C-reactive protein (CRP), plasminogen 
activator inhibitor-1 (PAI-1), inflammatory interleukins and 
cytokines, etc. Moreover, it is now known that patients with 
a state of chronic inflammation, such as ESRD patients, have 
an increased expression and function of leukocyte 5-LOX,43 
the enzyme that regulates leukotriene synthesis but also 
lipid peroxidation, ROS production, mitochondrial damage, 
and leukocyte apoptosis, thereby providing a putative link 
between inflammation and oxidative stress.
Lessons learnt from vitamin e-coated 
membrane dialyzers
In line with α-Τ supplementation studies, studies in ESRD 
patients on chronic hemodialysis with the use of vitamin E 
coated dialyzer membrane, a membrane anticipated to exert 
antioxidative effects through the in situ action of α-Τ on the 
constituents of the blood that come in contact with it44,45 have 
shown various anti-inflammatory and antioxidative effects.46–60 
It is interesting that these effects took place either in com-
bination with an increase in the levels of plasma α-Τ or not 
(Table 2), a finding which means that anti-inflammatory and 
antioxidative effects of α-Τ are probably regulated not as much 
by its levels in the systemic circulation, but rather by other 
pharmacokinetic factors, such as the type of the α-Τ molecule 
used, the form of the drug, the dosing, the duration of therapy or 
the special pharmacokinetic conditions encountered in specific 
patient subpopulations. Furthermore, we have preliminary 
data in ESRD patients showing that anti-inflammatory effects 
of vitamin E-coated membranes precede its antioxidative 
effects (unpublished data). In this case, the beneficial effects 
of the membrane-bound α-Τ probably take place through the 
protection it provides to circulating leukocytes against their 
repeated activation by the otherwise bioincompatible synthetic 
dialysis membrane and the abatement of the inflammatory 
reaction might secondarily lead to the antioxidative effects 
of α-Τ. As long as atherosclerosis is a chronic inflammatory 
process as well, these findings might point towards a probably 
selective or potentiated effectiveness of α-Τ in patients with 
chronic inflammation and, to this extent it is interesting that 
none of the large randomized, controlled trials ever studied 
in separate patients with chronic inflammation.
indications and target of treatment
It is also possible that the patients included in these trials 
were inappropriate for testing the hypothesis. One universal 
characteristic of all relevant studies is the lack of specific 
indications for the treatment with α-Τ supplementation, apart 
for the high cardiovascular risk of the patients. In contrast with 
other medications expected to confer cardiovascular benefits, 
such as statins, α-Τ has been given indiscriminately to all 
patients at high cardiovascular risk. Thus, while in all studies 
which found a benefit on the primary endpoint, a significant 
increase in the respective plasma antioxidant levels was 
reported, in the opposite, in only four of the seven negative 
studies were antioxidant levels reported. It is characteristic 
that no clinical trials hitherto have been performed in which 
patient inclusion was based on concrete criteria concerning 
markers of oxidative stress, even though patients who do 
not have increased oxidative stress would not be expected 
to benefit particularly from antioxidant therapy. The efficacy 
of exogenous antioxidants in in vitro systems as well as in 
several clinical studies was highly conditioned by the degree 
of depletion of the diverse repertoire of endogenous antioxi-
dant defenses. Thus, inclusion of patients who did not exhibit 
evidence of oxidant stress in vivo presumably could have 
diluted the population susceptible to benefit and undermined 
the sample size calculations for the clinical trials. Furthermore, 
with respect to α-Τ supplementation and LDL oxidation, there 
are responders and nonresponders, and this could explain 
the null results in certain studies. The form of α-Τ might be 
crucial with regards to nonantioxidant effects.61 Although 
both RRR- and synthetic α-Τ (all-rac-α-Τ) have been shown 
by various groups to decrease LDL oxidation, with respect to 
cell signaling and inflammation (inhibition of protein kinase-C 
and decreasing the release of pro-inflammatory cytokines), it 
might be crucial for α-Τ to transfer from the plasma membrane 
to the cytosol. The importance of intracellular transfer of 
α-Τ by tocopherol associated protein (TAPS) might play a 
pivotal role in this regard. Thus, as long as TAPS mutations 
have been implicated in other pathologies with vitamin E 
deficiency,62 nonresponding to vitamin E supplementation 
in the aforementioned trials (cardiovascular endpoints or 
biomarkers), might be attributed to mutations in TAPS and 
other relevant biomolecules that are important in orchestrating 
both the antioxidant and nonantioxidant effects of α-Τ.
Moreover, although several studies included smokers who 
would be anticipated to be in a state of increased inflamma-
tion, actually no measure of biomarkers of inflammation was 
reported in any of the studies, and it has recently been shown 
that α-Τ is indeed anti-inflammatory, reducing monocyte pro-
inflammatory cytokines and high-sensitivity CRP levels.63,64 
As long as there is solid evidence that chronic inflammation 
is a pivotal player in the atherogenetic process in interplay Vascular Health and Risk Management 2009:5 772
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with oxidative stress, the benefits from the treatment could be 
observed in special patient populations, such as diabetics or 
ESRD patients, ie patients with high degrees of both oxidative 
stress and chronic inflammation. These concerns have not been 
taken into account in any of the major studies of α-Τ benefits 
up to now and may be a crucial obstacle for the documentation 
of the real cardiovascular benefits which vitamin E probably 
confers in particular patients. As stated before, 5-LOX is 
one of the enzymes through which α-Τ exerts its actions,65 
and its increased expression and function in ESRD patients 
might represent one possible mechanism for a selective 
effect of α-Τ in these patients, in resemblance to the greatest 
cardiovascular benefits that statins have been shown to exert 
selectively in patients with inflammation.66 Finally, of concern 
is the observation that α-Τ has a dual function and can have in 
some cases pro-oxidative rather than antioxidative effects,67,68 
a characteristic that increases even more the necessity for the 
application of solid indications for treatment.
Conclusions
Several in vitro and in vivo studies have provided solid 
evidence regarding the antiatherogenic effects of α-T. 
Table 2 Summarized results in studies of the antioxidative and anti-inflammatory effects of vitamin E-coated membrane dialyzers
Authors Duration Patient number Control membrane Results
Galli46 3 months 15 Cuprammonium •  ↑ Levels of vitamins e and C  
•  ↓ Lipid peroxidosis  
•  ↓ROS and NO synthesis by leukocytes  
•  ↓ Apoptosis of monocytes and U937 cells
Mune47 2 years 25 Cellulose •  ↓ MDA and oxLDL  
•  Reduced aorta calcification  
•  No effects on plasma vitamin e levels
Girndt48 4 weeks 21 Hemophane/Polyamide •  ↓ intradialytic iL-6 production  
•  ↑ In vitro peripheral blood   T-lymphocyte proliferation
Tarng49 3–8 weeks 24 Various •  ↓ Oxidative damage of DNA (8-OHdG)  
•  ↓ ROS synthesis by leukocytes  
•  ↑ Levels of vitamin e
eiselt50 3 months 20 Cellulose •  ↓ intradialytic lipid peroxidation  
•  Long term ↓ of TBARS levels
Satoh51 6 months 18 Cellulose •  Suppression of intradialytic increase in MDA,   AGe and 8-OHdG   
•  Long term ↓ of MDA,   AGe and 8-OHdG
Clermont52 1 month 16 Polyacrylonitrile •    ↓ Of oxidative stress (↑ levels of vitamin C/stable AFR/vitamin 
C ratio)
•  ↓ Of intradialytic leukocyte activation
Tsuruoka53 10 months 10 Hemophane •  Long term ↓ of LDL and peroxides  
•    Long term ↓ of leukocytoopenia and intradialytic ↓ of oxLDL 
and MDA levels
Usberti54 7 months 10 Various •  ↓ Of MDA-4HNe and oxLDL  
•  ↑ Of vitamin e levels  
•  ↑ Survival of red blood cells  
•  No changes in TAS and thiol levels
Pertosa55 3 months 8 Cellulose •  Suppression of C5b-9 increase  
•  ↓ Of iNOS expression and leukocyte JNK levels
Hara56 12 months 13 Various •  ↓ Of oxLDL
Betjes57 8 weeks 14 Hemophane/ 
Polysulfone
•    ↓ Monocyte expression of MHC-Ι, CD54, CD40, CD86 and 
iCAM-1
•  ↑ Lectin-induced   T-lymphocyte proliferation
Morimoto58 6 months 16 Polysulfone •  Long term ↓ of ADMA, oxLDL and MDA-LDL levels
Baragetti59 32 weeks 8 Cellulose •  ↓ Of AGe and pentosidine
Libetta60 12 months 10 Cellulose •  ↓ Production of iL-4, iL-10 and iFN-γ by CD4+ monocytes  
•  ↓ Production of iL-12 and iL-18 by peripheral blood monocytes  
•  ↑ Levels of vitamin e
•  ↓ Plama NO levels
Abbreviations: LDL, low-density lipoproteins; ROS, reactive oxygen species; NO, nitric oxide; oxLDL, oxidized LDL; iL, interleukin; 8-OHdG, 8-hydroxydeoxyguanosine; 
TBARS, thiobarbituric acid reactive substances; AGe, advanced glycation end-products;    AFR, ascorbyl free radicals; MDA-4HNe, malondialdehyde 4-hydroxynonenal;    TAS, 
total antioxidant status; iNOS, inducible nitric oxide synthase;  JNK, c-Jun N-terminal kinase; MHC, major histocombatibility complex; iCAM, intercellular adhesion 
molecule;    ADMA, asymmetric dimethylarginine; iFN-γ, interferon-γ.Vascular Health and Risk Management 2009:5 773
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The discrepancy between the findings in the observational 
and intervention studies could be well attributed to inherent 
difficulties in the study of the beneficial effects of α-Τ but 
also to deficiencies in the design of the studies performed 
until now. Further even more prolonged studies especially in 
specific patient subpopulations, ie, patients with increased 
oxidative stress and/or chronic inflammation, with the use 
of more delicate determination of the oxidative status of the 
patients and probably more efficient pharmacologic forms, 
are warranted in order to permit a more accurate estimation 
of the cardiovascular efficacy of α-Τ.
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